Altamira Therapeutics ^None

Altamira Therapeutics is a pharmaceutical company that focuses on developing innovative therapies for neurotologic disorders that affect the inner ear. They have two projects in advanced clinical development, Keyzilen\xae and AM-111, for the treatment of acute inner ear tinnitus and hearing loss, respectively. They also have AM-125 in early clinical development for the treatment of vertigo. Additionally, they collaborate with academic institutions to strengthen their pipeline. Altamira Therapeutics is involved in RNA therapeutics, allergy and viral infections, and inner ear disorders.